赛托生物
(300583)
| 流通市值：32.24亿 | | | 总市值：32.86亿 |
| 流通股本：1.86亿 | | | 总股本：1.90亿 |
| 报告期 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 流动资产: | | | | |
| 货币资金 | 229,945,988.16 | 255,962,580.48 | 148,445,436.47 | 258,727,186.35 |
| 应收票据及应收账款 | 251,322,996.55 | 201,425,299.6 | 226,439,613.49 | 304,015,815.01 |
| 应收账款 | 251,322,996.55 | 201,425,299.6 | 226,439,613.49 | 304,015,815.01 |
| 应收款项融资 | 139,453,648.22 | 135,282,379.06 | 211,751,912.67 | 197,685,245.86 |
| 预付款项 | 9,688,739.64 | 7,780,152.91 | 27,214,522.94 | 18,065,397.44 |
| 其他应收款合计 | 13,942,353.83 | 13,038,620.68 | 16,847,378 | 19,649,711.47 |
| 存货 | 550,279,833.26 | 644,877,938.66 | 690,194,330.29 | 682,750,304.39 |
| 其他流动资产 | 22,796,588.98 | 26,549,191.26 | 23,726,974.01 | 21,603,184.21 |
| 流动资产平衡项目 | 0 | 0 | 0 | 0 |
| 流动资产合计 | 1,217,430,148.64 | 1,284,916,162.65 | 1,344,620,167.87 | 1,502,496,844.73 |
| 非流动资产: | | | | |
| 长期股权投资 | 67,318,247.18 | 68,677,871.46 | 69,490,845.46 | 68,292,565.69 |
| 固定资产 | 1,128,780,125.02 | 1,169,951,016.19 | 1,119,845,035.9 | 1,140,022,109.81 |
| 在建工程 | 307,842,847.95 | 281,700,000.48 | 344,091,869.77 | 310,905,223.34 |
| 使用权资产 | 8,206,498.97 | 9,008,011.8 | 4,822,888.07 | 7,569,902.78 |
| 无形资产 | 187,415,383.32 | 189,154,137.38 | 190,291,235.89 | 192,141,729.5 |
| 长期待摊费用 | 657,276.18 | 785,937.33 | 914,598.48 | 1,043,259.63 |
| 递延所得税资产 | 13,941,355.12 | 16,198,352.27 | 7,901,496.86 | 7,673,939.84 |
| 其他非流动资产 | 4,825,614.54 | 5,415,292.97 | 5,171,496.68 | 5,269,029.44 |
| 非流动资产平衡项目 | 0 | 0 | 0 | 0 |
| 非流动资产合计 | 1,718,987,348.28 | 1,740,890,619.88 | 1,742,529,467.11 | 1,732,917,760.03 |
| 资产平衡项目 | 0 | 0 | 0 | 0 |
| 资产总计 | 2,936,417,496.92 | 3,025,806,782.53 | 3,087,149,634.98 | 3,235,414,604.76 |
| 流动负债: | | | | |
| 短期借款 | 662,574,103.57 | 642,556,170.71 | 618,426,438.25 | 656,358,357.56 |
| 应付票据及应付账款 | 235,766,608.31 | 307,429,290.64 | 293,393,765.79 | 304,898,369.06 |
| 其中：应付票据 | 86,009,926.41 | 136,427,270.65 | 159,523,971.7 | 139,373,098.69 |
| 应付账款 | 149,756,681.9 | 171,002,019.99 | 133,869,794.09 | 165,525,270.37 |
| 合同负债 | 4,032,803.61 | 4,790,455.65 | 5,308,999.12 | 5,259,248.56 |
| 应付职工薪酬 | 8,075,913.02 | 10,364,524.24 | 8,868,254.27 | 8,691,447.33 |
| 应交税费 | 8,557,583.88 | 4,336,418.44 | 12,897,214.91 | 12,721,894.97 |
| 其他应付款合计 | 16,714,283.58 | 14,519,575.38 | 16,471,765.67 | 102,620,916.37 |
| 应付股利 | - | - | - | 85,365,956.7 |
| 一年内到期的非流动负债 | 40,146,255.84 | 39,152,925.84 | 19,047,937.43 | 19,135,046.91 |
| 其他流动负债 | 474,804.32 | 522,534.41 | 474,871.48 | 128,179.13 |
| 流动负债平衡项目 | 0 | 0 | 0 | 0 |
| 流动负债合计 | 976,342,356.13 | 1,023,671,895.31 | 974,889,246.92 | 1,109,813,459.89 |
| 非流动负债: | | | | |
| 长期借款 | 68,651,892.21 | 74,282,737.63 | 51,862,836 | 57,436,000.73 |
| 租赁负债 | 4,630,180.29 | 5,316,959.73 | 3,002,861.42 | 6,366,700.75 |
| 长期应付款 | 11,558,980.13 | 16,373,310.8 | 35,909,979.28 | 39,703,157.42 |
| 递延收益 | 22,412,740.78 | 21,329,376.67 | 22,130,912.1 | 22,936,441.7 |
| 递延所得税负债 | 609,338.36 | 667,552.85 | 659,924.25 | 694,677.8 |
| 非流动负债平衡项目 | 0 | 0 | 0 | 0 |
| 非流动负债合计 | 107,863,131.77 | 117,969,937.68 | 113,566,513.05 | 127,136,978.4 |
| 负债平衡项目 | 0 | 0 | 0 | 0 |
| 负债合计 | 1,084,205,487.9 | 1,141,641,832.99 | 1,088,455,759.97 | 1,236,950,438.29 |
| 所有者权益(或股东权益): | | | | |
| 实收资本(或股本) | 189,702,126 | 189,702,126 | 189,702,126 | 189,702,126 |
| 资本公积 | 1,276,956,870.47 | 1,276,956,870.47 | 1,276,956,870.47 | 1,276,956,870.47 |
| 盈余公积 | 93,766,209.97 | 93,766,209.97 | 93,766,209.97 | 93,766,209.97 |
| 未分配利润 | 251,187,826.15 | 278,696,334.13 | 382,178,378.18 | 380,674,422.91 |
| 归属于母公司股东权益平衡项目 | 0 | 0 | 0 | 0 |
| 归属于母公司股东权益合计 | 1,811,613,032.59 | 1,839,121,540.57 | 1,942,603,584.62 | 1,941,099,629.35 |
| 少数股东权益 | 40,598,976.43 | 45,043,408.97 | 56,090,290.39 | 57,364,537.12 |
| 股东权益平衡项目 | 0 | 0 | 0 | 0 |
| 股东权益合计 | 1,852,212,009.02 | 1,884,164,949.54 | 1,998,693,875.01 | 1,998,464,166.47 |
| 负债和股东权益合计 | 2,936,417,496.92 | 3,025,806,782.53 | 3,087,149,634.98 | 3,235,414,604.76 |
| 公告日期 | 2025-04-29 | 2025-04-29 | 2024-10-29 | 2024-08-27 |
| 审计意见(境内) | | 标准无保留意见 | | |